Home › Non-Small Cell Lung Cancer › Ohio › Cincinnati
Pag-aaral pangklinika para sa Non-Small Cell Lung Cancer sa Cincinnati, OH
Isang pag-aaral para sa Non-Small Cell Lung Cancer ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Cincinnati. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Nagre-recruitPhase 3
- University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0103), Cincinnati
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Nagre-recruitPhase 3
- University of Cincinnati Medical Center ( Site 0119), Cincinnati
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Nagre-recruitPhase 3
- The Christ Hospital, Cincinnati
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Nagre-recruitPhase 3
- Local Institution - 0383, Cincinnati
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Nagre-recruitPhase 3
- University of Cincinnati Cancer Center, Cincinnati
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Nagre-recruitPhase 3
- TriHealth Cancer & Blood Institute Research, Cincinnati
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Nagre-recruitPhase 3
- Oncology_Hematology Care Clinical Trials,LLC, Cincinnati
- Oncology_Hematology Care Clinical Trials,LLC, Cincinnati
- Oncology_Hematology Care Clinical Trials,LLC, Cincinnati
- at 1 pa
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Nagre-recruitPhase 3
- Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0061), Edgewood · 8 mi ang layo
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Nagre-recruitPhase 3
- Oncology Hematology Care Clinical Trials, Cincinnati
- Oncology Hematology Care Clinical Trials, Cincinnati
- Oncology Hematology Care Clinical Trials, Cincinnati
- at 1 pa
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Nagre-recruitPhase 2
- Cincinnati Veterans Affairs Medical Center, Cincinnati
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Nagre-recruitPhase 3
- Research Site, Cincinnati
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Nagre-recruitPhase 3
- University of Cincinnati Medical Center, Cincinnati
- Saint Elizabeth Medical Center Edgewood, Edgewood · 8 mi ang layo
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Nagre-recruitPhase 3
- Saint Elizabeth Medical Center Edgewood, Edgewood · 8 mi ang layo
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Nagre-recruitPhase 2/3
- The Christ Hospital Cancer Center, Cincinnati
- University of Cincinnati Medical Center, Cincinnati
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Nagre-recruitPhase 3
- Research Site, Cincinnati
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Nagre-recruitPhase 3
- Clinical Study Sites, Cincinnati
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Nagre-recruitPhase 2/3
- Local Institution - 007-893-B, Cincinnati
- USOR - Oncology Hematology Care - Blue Ash, Cincinnati
- Local Institution - 007-893-C, Cincinnati
- at 1 pa
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Nagre-recruitPhase 2/3
- Oncology Hematology Care, Inc - Blue Ash /ID# 262733, Cincinnati
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Nagre-recruitPhase 1/2
- Christ Hospital, Cincinnati
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Nagre-recruitPhase 3
- USO - Oncology Hematology Care, Cincinnati
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Nagre-recruitPhase 1
- University of Cincinnati (UC) - Cancer Institute, Cincinnati
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Nagre-recruitPhase 1
- St. Elizabeth Healthcare, Edgewood · 8 mi ang layo
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
Nagre-recruitPhase 3
- University of Cincinnati Medical Center, Cincinnati
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Nagre-recruitPhase 2
- University of Cincinnati Medical Center, Cincinnati
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Nagre-recruitPhase 1/2
- University of Cincinnati, Cincinnati
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Nagre-recruitPhase 1
- The Christ Hospital, Cincinnati
MYLUNG Consortium Part 3: Observational Study
Nagre-recruitObservasyonal na pag-aaral
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Nagre-recruitPhase 1/2
- Christ Hospital Cancer Center, Cincinnati
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 2
- St. Elizabeth Healthcare, Edgewood · 8 mi ang layo
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Nagre-recruitPhase 1/2
- Carl & Edyth Lindner Center for Research & Education at The Christ Hospital and The Christ Hospital Cancer Center, Cincinnati
Promoting Immunotherapy Efficacy With Low-Dose Liver RT
Nagre-recruit
- University of Cincinnati Medical Center, Cincinnati
GEMINI-NSCLC: NSCLC Biomarker Study
Nagre-recruitObservasyonal na pag-aaral
- TriHealth Cancer Institute, Cincinnati
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Nagre-recruitPhase 1/2
- Research Site 113, Cincinnati
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Nagre-recruitObservasyonal na pag-aaral
- Massive Bio SYNERGY-AI site, Cincinnati
A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.
Nagre-recruitPhase 2
- The Christ Hospital, Cincinnati
Pag-aaral para sa Non-Small Cell Lung Cancer sa ibang lungsod
- Houston, TX145 pag-aaral
- New York City, NY121 pag-aaral
- Arlington, VA104 pag-aaral
- Nashville, TN97 pag-aaral
- Boston, MA90 pag-aaral
- Los Angeles, CA87 pag-aaral
- St. Louis, MO73 pag-aaral
- Chicago, IL61 pag-aaral
- Baltimore, MD60 pag-aaral
- San Antonio, TX59 pag-aaral
- Columbus, OH57 pag-aaral
- Washington, DC55 pag-aaral
Iba pang pag-aaral sa Cincinnati
- Kanser (lahat ng uri)27 pag-aaral
- Kanser sa Suso25 pag-aaral
- Pagkabigo ng Puso24 pag-aaral
- Colorectal Cancer21 pag-aaral
- Metastatic Cancer21 pag-aaral
- Acute Myeloid Leukemia20 pag-aaral
- Kanser sa Ovary19 pag-aaral
- Obesity19 pag-aaral
- Kanser sa Baga19 pag-aaral
- Kanser sa Prostate18 pag-aaral
- Melanoma17 pag-aaral
- Multiple Myeloma17 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.